about
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationThe challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective.Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.Bone marrow micrometastases in early breast cancer-30-year outcome.Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction)Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.Conducting non-commercial international clinical trials: the ICR-CTSU experience.Implementing electronic data capture (EDC) training for site staff.Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC).Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms.Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC).A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study.Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up.Exploring the role and functionality of trial steering committees.The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up.NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?Targeted radiotherapy for early breast cancer - Authors' reply.Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.Reply to Goodare et al. Re: Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy?Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer.FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies
P50
Q27027579-F2CDC10B-37FB-408A-ACC1-1D4C1510431BQ30369607-C4FC8C2B-0BFB-4917-9691-4416482B842FQ30855522-B3A4A038-1C14-4C71-9AA9-ED7D356C5454Q34199348-955ABC47-6243-4BD9-9BE4-724E3E75C4F9Q36534799-51B24C73-2884-4C5E-9E7C-84361F189E6CQ36547904-2938ED2D-A3A6-45E9-A4F4-1B5252D9B43AQ36758456-E61FDE51-1FEF-46BD-89AA-A473C240BB1AQ37207312-77E230D0-6B3B-4C44-8926-C89DD493217CQ37228373-5604E1C1-A719-4414-A61E-FCA6F89C154AQ38379925-C84F9FDC-4991-4D17-8721-9FA0E7734BE3Q38909247-2C48565D-A480-4B55-B282-9563DDE63B90Q39352887-C93DD4FD-7CC4-4B13-BA0B-75E9BC912AEDQ40488633-031B3485-BAF6-41BF-843C-17F43C6CFF42Q40777129-50E4E7A5-BBFC-4D3E-BBFB-3C91D4577127Q41721139-111AB92D-2C8A-4C0A-9C96-53C84B6C0478Q41721517-96DAEF64-FAE4-4A73-B614-4B79CDFACE97Q42364730-1378556C-910A-470E-8848-29177BA04BF8Q45978995-F760FA33-335B-4671-92B7-7D0806F05472Q45979497-96F78500-AC31-4667-88A5-4ADB960DC93DQ45983087-47276C0B-A1B7-4C65-99FB-ADCBD2226985Q45991366-77C27F98-194A-45B0-94BE-F61DD0D257C9Q45992076-2E2E4734-9E0B-4711-911E-BB3EE82DAB81Q45992683-FD2642FD-6597-4C58-8224-DFD79D82EDF4Q45994217-BC4D5F6C-A9C1-4321-85CC-81EB2EF763EFQ46425805-7857E1CC-28B8-4BD2-B686-85E549B69575Q47098946-F46E5379-FAB8-4AF4-A393-EF1ACF4B1A54Q47158945-CA7ED5AE-E294-44BC-8CAD-2D51DE839D6AQ47650906-7750624A-A160-4BEF-96A5-F1CC73AB296FQ48059912-D4622EA5-D680-4C0B-8198-A80C477AB18FQ48234773-93A90C45-4494-425E-B96A-84CD0E070142Q49218612-28F99667-4DE6-49F9-8A50-5603EAB727E7Q50056115-1814975D-45E5-4FFA-B411-C0BB617F5A80Q50091659-FB2B1BCA-C405-42C2-A682-C5AF92F3DD30Q52678229-41A095BE-0025-4764-8F79-B49359EDF31AQ52979030-47826CFB-6BE8-4C17-84B8-535D05EBBED7Q53004084-82A54DA9-57D6-43E7-8C02-804795DA9AFCQ54378040-431B4F75-F08C-4100-A33F-529635E10328Q55468519-33613722-4E0C-49C7-B8DC-B98AB497AC6BQ55514078-8D62E492-4372-4049-A363-E2608E6923DEQ57109510-D0131E25-31A7-46E2-A3D8-960D289C8A82
P50
description
investigador
@es
researcher
@en
name
Judith M Bliss
@en
type
label
Judith M Bliss
@en
prefLabel
Judith M Bliss
@en
P31
P496
0000-0001-7957-7424